Peer Review History

Original SubmissionOctober 2, 2020
Decision Letter - Weidong Le, Editor

PONE-D-20-31004

Representation of Parkinson's disease and atypical Parkinson's syndromes in the Czech Republic - A nationwide retrospective study

PLOS ONE

Dear Dr. Búřil,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jan 11 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Weidong Le

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.Thank you for stating the following financial disclosure:

 [The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.].

At this time, please address the following queries:

  1. Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.
  2. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”
  3. If any authors received a salary from any of your funders, please state which authors and which funders.
  4. If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3.We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4.We note that [Figure(s) 3] in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

1.    You may seek permission from the original copyright holder of Figure(s) [3] to publish the content specifically under the CC BY 4.0 license. 

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

2.    If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: I Don't Know

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In this manuscript, the authors reported a retrospective analysis of data available from the National Health Information System – NHIS and the National Registry of Reimbursed Health Services (NRRHS) with respect to the STROND checklist to determine the prevalence and other epidemiological features of Parkinsonism in the Czech Republic. Data on parkinsonian syndromes (Parkinson's disease and mainly Atypical Parkinsonian syndromes) in different Eastern European countries are scarce and this study could be valuable by depicting epidemiological features of these diseases in understudied populations. However, some changes should be reconsidered.

Abstract:

The aim of the study is not well stated.

The results are not well defined (what do the authors mean by "We identified 78 453 patients? this figures stands for what exactly?

The conclusion part of the abstract included data not previously presented in the results. This should be addressed.

Introduction:

The aim at the end of the introduction part is not clearly stated " to elucidate a number of patients treated for PD in the Czech Republic". The authors should be more specific. They stated later in the Materials and Methods part: " We analyzed epidemiological data intending to determine the regional and specific prevalence of Parkinsonism in the Czech Republic." Objectives should be mentioned all together at the end of the Introduction part.

Materials and Methods:

- The authors should define the exact meaning of the different codes used in this part : " The International Classification of Diseases 33 (ICD-10) diagnoses of G20 (Parkinson’s disease) and G23.1, G23.2, G23.3 (other degenerative disorders of basal ganglia), and G31.8 (another degenerative disease of basal ganglia)"

-How do the authors explain the fact the diagnosis G23.3 (according to ICD-10) was not found in the analyzed data? and why did they decide to excluded this diagnosis from further evaluation? This is a result they could discuss later on in the discussion part.

-What do the authors mean by " regional" and "specific" prevalence of Parkinsonism. This should be better specified in the Methods part.

-What do the authors mean by: " Atypical parkinsonian syndromes were 36 included due to overlap of clinical signs, at least during the initial stages of Parkinsonism."? How does this affect their methodology? this should be better explained.

-The authors should precise all the data analyzed later in the results in the methodology part.

Results:

-What do the authors mean by "we identified 78 453 patients" and then "were registered as the principal diagnoses in 76.6 % of all individual patients"? What does the first figure stand for? all patients with "any disease"? what does the percentage stand for?

-The authors stated at the end of this section: "Various genetic and social factors may influence the regional distribution of patients with Parkinsonism, as was already reported in the eastern part of our country. [13]". This should be rather put in the discussion section and better explained.

-In the sentence: " The ratio of the parkinsonian subtype of PSP (PSP-P) to the cerebellar subtype is 2:1 to 4:1 in 66 most countries. [15, 16]", the authors are rather talking about MSA and not PSP. This should be amended.

-Other minor changes suggested:

• The quality of figures and tables should be

Reviewer #2: In this manuscript, the authors attempted to determine epidemiological features of parkinsonian syndromes in the Czech Republic by a retrospective analysis of data available from the NHIS and the NRRHS. Further studies, such this one, on epidemiology of parkinsonism especially atypical parkinsonian syndromes are needed. However the authors should clarify some points, as follows:

1-The aim/objectives of the study is not well stated in the abstract and later in the introduction.

2- The authors should explain the exact meaning of the different codes used in the methodology part and precise all items/parameters that will be later detailed in the results

3-The results are not well defined both in the abstract and in the manuscript

4-The sentence "Various genetic and social factors may influence the regional distribution of patients with Parkinsonism, as was already reported in the eastern part of our country. [13]" should be in the discussion section.

5-The quality of figures and tables could be improved.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

The aim of the study is not well stated. Reviewer #1 The aim was stated:

Aim of the analyses: The main aim of our analyses was to identify the number of reported patients with Parkinson's disease (PD) – dg. G-20 (ICD-10) from the national health registries.

The results are not well defined (what do the authors mean by "We identified 78 453 patients? this figures stands for what exactly? Reviewer #1 Accepted – Thank you so much for this comment, we clarified it.

The conclusion part of the abstract included data not previously presented in the results. This should be addressed. Reviewer #1 Accepted – The data were included in the results section.

Introduction:

The aim at the end of the introduction part is not clearly stated" to elucidate a number of patients treated for PD in the Czech Republic". The authors should be more specific. They stated later in the Materials and Methods part: "We analyzed epidemiological data intending to determine the regional and specific prevalence of Parkinsonism in the Czech Republic." Objectives should be mentioned all together at the end of the Introduction part. Reviewer #1 The clearly stated aim of the study was added as an extra section between “Introduction” and “Materials and Methods”.

Materials and Methods:

The authors should define the exact meaning of the different codes used in this part: "The International Classification of Diseases 33 (ICD-10) diagnoses of G20 (Parkinson’s disease) and G23.1, G23.2, G23.3 (other degenerative disorders of basal ganglia), and G31.8 (another degenerative disease of basal ganglia)" Reviewer #1 Accepted – the data were analysed based on the record and codes reported by clinicians to the National health registries.

How do the authors explain the fact the diagnosis G23.3 (according to ICD-10) was not found in the analyzed data? and why did they decide to excluded this diagnosis from further evaluation? This is a result they could discuss later on in the discussion part. Reviewer #1 Accepted – the diagnosis G23.3 (according to ICD-10) was not found in the analyzed data – there were no record of the dg. G23.3 in the whole analysed dataset. The possible reason is, that there were no incidence of patients with dg. G23.3 which could relate to the problem that the clinicians are unable to diagnose it appropriately. Also published literature is confirming that the dg. G23.3 is not reported, the commonly used codes are 23.1, 23.2 and 23.9 (Harding, Z. 2019 https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0198736&type=printable).

Another possibility is that the clinicians do not show dg. multisystem atrophies correctly under the code G 23.3, but under the general one, for example G31.8.

What do the authors mean by "regional" and "specific" prevalence of Parkinsonism. This should be better specified in the Methods part. Reviewer #1 Accepted - there is no change in the methodology of data extraction. The regional analyses have been done based on the place where the care was provided – we have added information to the discussion section.

What do the authors mean by: "Atypical parkinsonian syndromes were 36 included due to overlap of clinical signs, at least during the initial stages of Parkinsonism."? How does this affect their methodology? this should be better explained. Reviewer #1 Accepted – there was no effect on the methodology – as we have included all the diagnoses mentioned in the methodology section. When we tried to identify only G20 – the data would not be accurate – it is based on the author’s clinical experiences with recording in the Czech Republic.

The authors should precise all the data analyzed later in the results in the methodology part. Reviewer #1 Accepted – double checked.

Results:

What do the authors mean by "we identified 78 453 patients" and then "were registered as the principal diagnoses in 76.6 % of all individual patients"? What does the first figure stand for? all patients with "any disease"? what does the percentage stand for? Reviewer #1 Accepted - The information was more precisely explained: We identified 205 490 records of patients with PD from national registries in the period from 2012 to 2018 (averaging 29 000 patients per year, shown in Fig.1), which means 78 453 unique patients in total (each patient could be recorded just one time during the year, but several times during the whole period from 2012 to 2018). We have found a growing number of records coded with ICD-10 of dg. G20, G23.1, G23.2, or G31.8 (N = 27 891 in 2012, and N = 30 612 in 2018).

The authors stated at the end of this section: "Various genetic and social factors may influence the regional distribution of patients with Parkinsonism, as was already reported in the eastern part of our country. [13]". This should be rather put in the discussion section and better explained. Reviewer #1 Accepted - we add the information in the discussion section.

In the sentence: "The ratio of the parkinsonian subtype of PSP (PSP-P) to the cerebellar subtype is 2:1 to 4:1 in 66 most countries. [15, 16]", the authors are rather talking about MSA and not PSP. This should be amended. Reviewer #1 Accepted - sorry for the misinterpretation – the text was changed.

Other minor changes suggested:

• The quality of figures and tables should be Reviewer #1 We could not address this comment – maybe the comment was not finished?

The aim/objectives of the study is not well stated in the abstract and later in the introduction. Reviewer #2 The aim was stated: Aim of the analyses: The demographic description of reported patients with Parkinson's disease according to the International Classification of Diseases (ICD-10) from the national health registries. (in shortened version also in abstract).

The authors should explain the exact meaning of the different codes used in the methodology part and precise all items/parameters that will be later detailed in the results Reviewer #2 Accepted – double checked and added explanations.

The results are not well defined both in the abstract and in the manuscript Reviewer #2 Accepted – double checked and added explanations.

The sentence "Various genetic and social factors may influence the regional distribution of patients with Parkinsonism, as was already reported in the eastern part of our country. [13]" should be in the discussion section. Reviewer #2 Accepted - we add the information in the discussion section.

The quality of figures and tables could be improved. Reviewer #2 The figures are used from the data analyses system – we have no possibility to improve the quality.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. Editor Accepted – Thank you so much.

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.” Editor The authors received no specific funding for this work.

We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide. Editor There is legal restrictions on sharing data publicly – all the data form the National registries must be kept safely and authors are working with the anonymised data. For the data you can ask the head of the department of data Analyses team from the Institute of Health Information and Statistics of the Czech Republic - Dr. Jiří Jarkovský (email: Jiri.Jarkovsky@uzis.cz)

We note that [Figure(s) 3] in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

1. You may seek permission from the original copyright holder of Figure(s) [3] to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful... Editor The figure no. 3 was produced by our author’s team. We have published this kind of figure with different type of health data has been already published without any need for copyrighted.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Weidong Le, Editor

PONE-D-20-31004R1

Representation of Parkinson's disease and atypical Parkinson's syndromes in the Czech Republic - A nationwide retrospective study

PLOS ONE

Dear Dr. Búřil,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 13 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Weidong Le

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: (No Response)

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Most of the required modifications were amended. However, minor revisions are still needed:

1-In the abstract and in the manuscript: in the aim of the study, " The demographic description of reported patients with Parkinson's disease"==> The demographic description of reported patients with parkinsonism (including Parkinson's disease and atypical parkinsonian syndromes): the aim should be in accordance with the article title.

2-The authors should precise all the data analyzed later in the results in the methodology part. This was not amended.

3-The quality of figures and tables should be improved.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 2

In the abstract and in the manuscript: in the aim of the study, " The demographic description of reported patients with Parkinson's disease"==> The demographic description of reported patients with parkinsonism (including Parkinson's disease and atypical parkinsonian syndromes): the aim should be in accordance with the article title.

Accepted – the aim has been reworded according the reviewer´s comment.

The authors should precise all the data analyzed later in the results in the methodology part. This was not amended.

Accepted – the information in the methodology part has been added.

The quality of figures and tables should be improved.

Accepted – the figures were graphically edited and uploaded.

Attachments
Attachment
Submitted filename: Response to Reviewers_6_1_2021.docx
Decision Letter - Weidong Le, Editor

Representation of Parkinson's disease and atypical Parkinson's syndromes in the Czech Republic - A nationwide retrospective study

PONE-D-20-31004R2

Dear Dr. Búřil,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Weidong Le

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Formally Accepted
Acceptance Letter - Weidong Le, Editor

PONE-D-20-31004R2

Representation of Parkinson's disease and atypical Parkinson's syndromes in the Czech Republic - A nationwide retrospective study

Dear Dr. Búřil:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Weidong Le

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .